Crewe Advisors LLC Has $334,000 Holdings in Amgen Inc. (NASDAQ:AMGN)

Crewe Advisors LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 11.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,283 shares of the medical research company’s stock after selling 169 shares during the period. Crewe Advisors LLC’s holdings in Amgen were worth $334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen in the third quarter valued at approximately $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the 3rd quarter valued at approximately $29,000. Matrix Trust Co bought a new position in shares of Amgen during the third quarter valued at $36,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the fourth quarter worth $36,000. Finally, Livelsberger Financial Advisory bought a new stake in shares of Amgen in the third quarter worth $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 6.5 %

NASDAQ AMGN opened at $307.81 on Thursday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The company has a market capitalization of $165.46 billion, a PE ratio of 39.41, a P/E/G ratio of 2.87 and a beta of 0.56. The company has a fifty day moving average of $271.14 and a 200 day moving average of $303.52.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Research analysts forecast that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is 115.24%.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. William Blair reiterated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Wolfe Research assumed coverage on shares of Amgen in a research report on Friday, November 15th. They set a “peer perform” rating for the company. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler decreased their price target on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a report on Thursday, January 2nd. Finally, TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Amgen has an average rating of “Hold” and a consensus target price of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.